0001737287-24-000021 Sample Contracts

COLLABORATION AND LICENSE AGREEMENT

Collaboration and License Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

• Contract Type
  Collaboration and License Agreement
• Filed
  March 14th, 2024
• Company
  Allogene Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

This Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of [***] (the “Restatement Effective Date”), is made by and between Allogene Therapeutics, Inc., a Delaware corporation with its principal place of business at 210 East Grand Ave., South San Francisco, CA 94080 (“Allogene”), and Notch Therapeutics (Canada) Inc., having an address at 300-2233 Columbia St, Vancouver, BC V5Y 0M6 (“Notch”). Allogene and Notch are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

STRATEGIC COLLABORATION AGREEMENT between FORESIGHT DIAGNOSTICS, INC. and ALLOGENE THERAPEUTICS, INC. Dated as of January 3, 2024 STRATEGIC COLLABORATION AGREEMENT

Strategic Collaboration Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  Strategic Collaboration Agreement
• Filed
  March 14th, 2024
• Company
  Allogene Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)

This Strategic Collaboration Agreement (this “Agreement”) is effective as of January 3, 2024 (the “Effective Date”) by and between Foresight Diagnostics, Inc., having a principal place of business at 2865 Wilderness Place, Boulder, CO 80301 (“Foresight”), and Allogene Therapeutics, Inc., having a principal place of business at 210 East Grand Avenue, South San Francisco, CA 94080 (“Company”). Foresight and Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

FIRST AMENDMENT TO CONSULTING AGREEMENT

Consulting Agreement • March 14th, 2024 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  Consulting Agreement
• Filed
  March 14th, 2024
• Company
  Allogene Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)

This First Amendment to the Consulting Agreement (“Amendment”) is made as of December 16, 2023 (“Amendment Effective Date”) by and between Alison Moore, Ph.D., having an address at 5 Hill Ave., San Carlos CA 94070 (“Consultant”) and Allogene Therapeutics, Inc., a Delaware corporation having an address at 210 E. Grand Ave., South San Francisco, CA 94080 (“Allogene”).